Kenneth A Burdick

Director Kenneth A Burdick sold 80,000 CNC shares at $64.55; stock up 7.1% in 30 days post-sale

Kenneth A Burdick, a Director at Centene, sold 80,000 shares ($5,164,000.00 value) on 2026-06-10 at $64.55, reducing his holdings by 80,000 shares from 277,085 to 197,085 shares. His prior two sales at CNC (2025-12-04 and 2025-12-03) both generated positive 90-day returns of +15.4% and +12.2%, respectively, indicating the stock moved up after those sales rather than down. The current stock price of $63.54 stands at -4.5% from the 52-week high of $66.55 and the stock has gained 7.1% over the past 30 days. This sale occurs within a company showing revenue growth of +19.4% year-over-year, though the company was unprofitable over its most recent full fiscal year despite posting net income of $1,541,000,000.00 in the latest quarter.

Director Burdick sells 66,007 CNC shares across 2 transactions at blended $39.02; reduces holdings by 19.5% to 272.4K shares

Kenneth A Burdick, a Centene director, executed 2 separate sales totaling 66,007 shares for $2,575,601.44 at an average price of $39.02 on December 3–4, 2025. The sale reduced his holdings from 338.4K to 272.4K shares, representing a 19.5% reduction of his pre-transaction position. The stock currently trades at $38.34, down 41.8% from its 52-week high of $65.89 but up 32.3% over the past 90 days, suggesting recent recovery from depressed levels. Centene's fundamentals show a recent quarter net loss of $6.6B against $49.7B in revenue, though annual revenue growth stands at 5.9%; the company trades at a P/E of 6.06. Within Burdick's cross-ticker insider trading history, his prior single sell was well-timed with a 100.00% well-timed rate (average 90-day return post-sale: -13.7%), though his prior buy pattern shows stronger conviction signals (5 buys with 100% 90-day win rate). This sale follows a material near-term rally (+32.3% in 90 days) and represents a meaningful yet not complete exit from his Centene position.

Director Burdick purchased 114,181 shares at blended average $4.36, totaling $498,293.90; stock down 43.0% from 52-week high.

Kenneth A Burdick, a Director at LifeStance Health Group, executed 5 separate purchases totaling 114,181 shares for $498,293.90 at an average price of $4.36 per share across two trading days (2025-08-08 and 2025-08-11). The current stock price of $4.66 reflects a decline of 43.0% from the 52-week high of $8.17, placing the purchase near depressed price levels. LifeStance reported negative net income of $-3,791,000 in its latest quarter and was unprofitable over its most recent full fiscal year, though the company showed revenue growth of 18.5% year-over-year. Burdick's single prior sale at LFST (2024-03-15) produced negative 90-day returns, demonstrating a historically well-timed exit pattern; however, his current multi-transaction buy program during a period of stock weakness and company losses does not necessarily represent market-timing skill and requires evaluation in the context of any pre-arranged trading plans or scheduled investments.